NYSEAMERICAN:TOVX Theriva Biologics (TOVX) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free TOVX Stock Alerts $0.47 -0.02 (-4.09%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$0.44▼$0.4950-Day Range N/A52-Week Range$0.20▼$1.20Volume42,268 shsAverage Volume102,955 shsMarket Capitalization$8.04 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsHeadlinesInsider TradesOwnershipShort InterestStock AnalysisChartEarningsHeadlinesInsider TradesOwnershipShort Interest Get Theriva Biologics alerts: Email Address Ad WealthPressA lot of people are making this costly mistakeYou may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. Click here to jump in on the next one About Theriva Biologics Stock (NYSEAMERICAN:TOVX)Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11. It has collaborations with The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.Read More TOVX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TOVX Stock News HeadlinesMarch 27, 2024 | seekingalpha.comTheriva Biologics, Inc. (TOVX) Q4 2023 Earnings Call TranscriptMarch 26, 2024 | finance.yahoo.comQ4 2023 Theriva Biologics Inc Earnings CallMarch 29, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…March 25, 2024 | globenewswire.comTheriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial ResultsMarch 22, 2024 | benzinga.comPreview: Theriva Biologics's EarningsMarch 19, 2024 | finanznachrichten.deTheriva Biologics, Inc.: Theriva Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial ResultsMarch 19, 2024 | globenewswire.comTheriva™ Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial ResultsMarch 11, 2024 | globenewswire.comTheriva™ Biologics to Participate in the BIO-Europe Spring ConferenceMarch 29, 2024 | Crypto 101 Media (Ad)Major Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.February 8, 2024 | msn.comTheriva Biologics Reports Positive Phase 2b Trial ProgressFebruary 8, 2024 | msn.comTheriva Biologics VIRAGE Trial Progresses PositivelyFebruary 7, 2024 | finance.yahoo.comTheriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal AdenocarcinomaJanuary 16, 2024 | finance.yahoo.comTheriva Biologics to Participate in the B. Riley Securities Annual Oncology ConferenceNovember 20, 2023 | finance.yahoo.comTheriva Biologics, Inc. (NYSE:TOVX) Q3 2023 Earnings Call TranscriptNovember 14, 2023 | finance.yahoo.comQ3 2023 Theriva Biologics Inc Earnings CallNovember 13, 2023 | msn.comTheriva Biologics GAAP EPS of -$0.19 beats by $0.23November 13, 2023 | finance.yahoo.comTheriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial ResultsNovember 10, 2023 | msn.comTheriva Biologics Q3 2023 Earnings PreviewNovember 10, 2023 | benzinga.comEarnings Outlook For Theriva BiologicsNovember 8, 2023 | morningstar.comTheriva Biologics Inc TOVXNovember 6, 2023 | finance.yahoo.comTheriva Biologics to Host Conference Call and Webcast to Discuss Third Quarter 2023 Operational Highlights and Financial ResultsNovember 2, 2023 | finance.yahoo.comTheriva™ Biologics to Participate in the BIO-Europe ConferenceNovember 2, 2023 | finance.yahoo.comTheriva™ Biologics and Sant Joan de Déu-Barcelona Children’s Hospital Advance Strategic Collaboration to Explore the Combination of VCN-01 with Topoisomerase Inhibitors to Treat CancerOctober 23, 2023 | finance.yahoo.comTheriva™ Biologics Presents Survival Outcomes Data from Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck at ESMO Congress 2023October 16, 2023 | finance.yahoo.comTheriva™ Biologics Announces Presentation at ESMO Congress 2023 Featuring Survival Outcomes in Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckOctober 14, 2023 | wsj.comSamsung Biologics Co. Ltd.September 28, 2023 | finance.yahoo.comTheriva Biologics to Participate in the Emerging Growth ConferenceSee More Headlines Receive TOVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Theriva Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/25/2024Today3/28/2024Next Earnings (Estimated)3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSEAMERICAN:TOVX CUSIPN/A CIKN/A Webtherivabio.com Phone(301) 417-4364Fax301-417-4367Employees21Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,680,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-42.93% Return on Assets-29.35% Debt Debt-to-Equity RatioN/A Current Ratio4.07 Quick Ratio3.98 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.27 per share Price / Book0.14Miscellaneous Outstanding Shares17,150,000Free Float16,145,000Market Cap$8.04 million OptionableNot Optionable Beta1.45 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Steven A. Shallcross CPA (Age 63)CEO, CFO, Treasurer, Corporate Secretary & Director Comp: $997.67kDr. Vince Wacher Ph.D.Head of Product & Corporate DevelopmentDr. Michael Kaleko M.D.Ph.D., Senior Vice President of Research & DevelopmentDr. Ramon Alemany Ph.D.Senior VP of Discovery & Chairman of Scientific Advisory BoardMs. Lara M. GuzmanSenior Director of Project OperationsKey CompetitorsImmune TherapeuticsOTCMKTS:IMUNProtagenic TherapeuticsNASDAQ:PTIXCan-Fite BioPharmaNYSE:CANFAyala PharmaceuticalsNASDAQ:ADXSPasithea TherapeuticsNASDAQ:KTTAView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 146,183 shares on 3/11/2024Ownership: 2.151%Vanguard Group Inc.Sold 146,183 shares on 2/15/2024Ownership: 2.151%Citadel Advisors LLCBought 57,953 shares on 2/15/2024Ownership: 0.340%Steven A ShallcrossBought 26,000 shares on 6/6/2023Total: $16,380.00 ($0.63/share)View All Insider TransactionsView All Institutional Transactions TOVX Stock Analysis - Frequently Asked Questions Who are Theriva Biologics' major shareholders? Theriva Biologics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (2.15%), Vanguard Group Inc. (2.15%) and Citadel Advisors LLC (0.34%). View institutional ownership trends. How do I buy shares of Theriva Biologics? Shares of TOVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:TOVX) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry ResearchAI healthcare stock poised for 36,996% growth?Behind the MarketsMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theriva Biologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.